siRNA compounds for inhibiting NRF2
US8278287B2 · kind B2 · utility
3Cited by
23References
21Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 6, 2009 |
| Grant date | Oct 2, 2012 |
| Priority date | — |
| Expiry date | Apr 24, 2029 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2310/344
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
The present invention provides chemically modified siRNA compounds that target the Nrf2 gene and pharmaceutical compositions comprising same useful for treating or preventing the incidence or severity of a cancerous disease, particularly various lung cancers.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.